Type of recurrence is associated with disease-free survival after salvage surgery for locally recurrent rectal cancer

2021 ◽  
Author(s):  
Rosa M. Jimenez-Rodriguez ◽  
Jonathan B. Yuval ◽  
Charles-Etienne Gabriel Sauve ◽  
Isaac Wasserman ◽  
Piyush Aggarwal ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Salvage Surgery ◽  
Disease Free Survival ◽  
Recurrent Rectal Cancer ◽  
Free Survival ◽  
Locally Recurrent Rectal Cancer ◽  
Locally Recurrent ◽  
Disease Free

scholarly journals A Case of Long-term Disease-free Survival after Radiotherapy for Locally Recurrent Rectal Cancer

2013 ◽  
Vol 66 (6) ◽  
pp. 416-421
Author(s):  
Nobuyoshi Yamazaki ◽  
Akihiro Kobayashi ◽  
Yusuke Nishizawa ◽  
Masaaki Ito ◽  
Masanori Sugito ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Disease Free Survival ◽  
Recurrent Rectal Cancer ◽  
Free Survival ◽  
Locally Recurrent Rectal Cancer ◽  
Locally Recurrent ◽  
Disease Free

Effect and safety of proton beam therapy for locally recurrent rectal cancer.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 743-743
Author(s):  
Yusuke Ogi ◽  
Tomohiro Yamaguchi ◽  
Yusuke Kinugasa ◽  
Akio Shiomi ◽  
Hiroyasu Kagawa ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Proton Beam ◽  
Survival Rates ◽  
Proton Beam Therapy ◽  
Local Control Rate ◽  
Recurrent Rectal Cancer ◽  
Lateral Lymph Node ◽  
Free Survival ◽  
Locally Recurrent Rectal Cancer ◽  
Locally Recurrent

743 Background: The first choice of treatment for locally recurrent rectal cancer is surgical resection. However, the operation is often difficult with high perioperative risk. For surgically unfit cases, proton beam therapy (PBT) is proposed as the treatment option. However, its efficacy for locally recurrent rectal cancer remains unclear. Therefore, this study aimed to evaluate the efficacy and safety of PBT for locally recurrent rectal cancer. Methods: A total of 23 patients with locally recurrent rectal cancer who received PBT were retrospectively evaluated, from November 2005 to July 2014. Patients with single lesion, who refuse the radical surgical therapy, or who were considered unfit for the operation were included in this study. All patients were treated with 2.8Gy relative biological effectiveness (RBE)/fraction. Twenty-five irradiations were performed, with a total irradiation of 70Gy RBE. Unfit for operation criteria include invasion to the vertebra higher than the third sacrum or lateral lymph node recurrence after a lateral lymph node dissection. To assess the safety of PBT, adverse events were evaluated by using the Common Terminology Criteria for Adverse Effects (CTCAE version4.0). To assess the efficacy, the overall and relapse-free survival rates and local control rate were evaluated. Results: Sixteen patients were unfit for operation, and seven refused surgery. Three patients experienced Grade 3 late adverse events in the CTCAE (two ileum fistula and one urinary tract obstruction). The median follow-up time was 28.9 months. The 5-year overall and relapse-free survival rates were 47.6% and 20.2%, respectively. Fifteen patients (65.2%) showed distant metastasis or regrowth at the locally recurrent site. The 5-year local control rate was 39.0%. Ten patients (43.4%) showed regrowth at the proton beam irradiation site. Conclusions: PBT was relatively effective for locally recurrent rectal cancer with manageable adverse effects. Therefore, PBT may be considered as the therapeutic option for selected locally recurrent rectal cancer patients.

scholarly journals Report of a Long-term Disease Free Survivor after Sacropelvic Exenteration for Locally Recurrent Rectal Cancer.

1991 ◽  
Vol 44 (7) ◽  
pp. 1093-1097
Author(s):  
K. Kotake ◽  
Y. Koyama ◽  
J. Matsui ◽  
I. Ozawa ◽  
T. Inada ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Recurrent Rectal Cancer ◽  
Locally Recurrent Rectal Cancer ◽  
Locally Recurrent ◽  
Disease Free

A phase III randomized controlled trial comparing surgery plus adjuvant chemotherapy with or without preoperative chemoradiotherapy for locally recurrent rectal cancer: A Japan Clinical Oncology Group study (JCOG1801).

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. TPS263-TPS263
Author(s):  
Yuichiro Tsukada ◽  
Masaaki Ito ◽  
Naoki Nakamura ◽  
Yoshinori Ito ◽  
Hideaki Bando ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Adjuvant Chemotherapy ◽  
Preoperative Chemoradiotherapy ◽  
Local Relapse ◽  
Recurrent Rectal Cancer ◽  
Phase Iii ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Locally Recurrent Rectal Cancer ◽  
Locally Recurrent

TPS263 Background: Local recurrence is one of the most common forms of recurrence after curative resection for primary rectal cancer. Surgical resection is recommended for locally recurrent rectal cancer (LRRC) to achieve radical cure if the tumor is judged as resectable with negative margins. However, a high local re-recurrent risk after surgery is a major problem due to the difficulty of re-resection and the serious symptoms, such as pain or fistula, resulting from re-recurrence. Preoperative chemoradiotherapy (preCRT) is expected to improve local control after radical surgery for radiation naïve LRRC; however, high frequency of surgical complications after preCRT cannot be ignored. Due to the refractory nature and rarity of LRRC, the true impact of preCRT on oncological and surgical outcomes has not been clarified by clinical trials. The purpose of this study is to confirm the superiority of preCRT followed by surgery plus adjuvant chemotherapy over surgery plus adjuvant chemotherapy alone, in terms of local relapse-free survival for resectable LRRC. Methods: Eligibility criteria include resectable LRRC without distant metastasis, no prior pelvic irradiation, no prior surgery for LRRC, aged 20-80 years, and sufficient organ function. Eligible patients are randomized into the surgery and adjuvant chemotherapy (arm A) or preCRT followed by surgery and adjuvant chemotherapy (arm B). PreCRT consists of the standard dose of capecitabine and radiotherapy (50.4Gy). Adjuvant chemotherapy consists of mFOLFOX6, CAPOX, capecitabine, or 5FU+l-LV. The primary endpoint is local relapse-free survival (LRFS), and the secondary endpoints include overall survival, relapse-free survival, %R0 resection, incidence of adverse events, and quality of life after surgery. The 3-year LRFS of arm A is assumed to be 60% with a 13% increase expected in arm B. The sample size was calculated as 106 (53 per arm) with a one-sided alpha of 10%, power of 70%, and accrual period of 6 years. This trial was initiated on 19 August 2019. Clinical trial information: jRCTs031190076.

Long-term outcomes following salvage surgery for locally recurrent rectal cancer: A 15-year follow-up study

2020 ◽  
Vol 46 (6) ◽  
pp. 1131-1137 ◽  
Author(s):  
David P. Cyr ◽  
Francis SW. Zih ◽  
Bryan J. Wells ◽  
Jossie Swett-Cosentino ◽  
Ronald L. Burkes ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Salvage Surgery ◽  
Recurrent Rectal Cancer ◽  
Long Term Outcomes ◽  
Follow Up Study ◽  
Locally Recurrent Rectal Cancer ◽  
Locally Recurrent

Laparoscopic Salvage Surgery for Locally Recurrent Rectal Cancer

2014 ◽  
Vol 18 (7) ◽  
pp. 1319-1326 ◽  
Author(s):  
Toshiya Nagasaki ◽  
Takashi Akiyoshi ◽  
Masashi Ueno ◽  
Yosuke Fukunaga ◽  
Satoshi Nagayama ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Salvage Surgery ◽  
Recurrent Rectal Cancer ◽  
Locally Recurrent Rectal Cancer ◽  
Locally Recurrent
Sign in / Sign up

Export Citation Format

Share Document